Leukeran Uses, Dosage, Side Effects & More

Leukeran is an oral medication used in the treatment of certain types of cancer, primarily chronic lymphocytic leukemia (CLL) and various forms of lymphoma. This comprehensive guide aims to provide detailed information about Leukeran, including its composition, medical uses, dosage, side effects, interactions, warnings, and historical background.

Overview of Leukeran

Leukeran, also known by its generic name chlorambucil, is a chemotherapy medication that belongs to a class of drugs called alkylating agents. It works by interfering with the replication of cancerous cells, thereby preventing their growth and spread. Leukeran has been widely used for the treatment of chronic lymphocytic leukemia (CLL) and certain types of lymphomas, both Hodgkin and non-Hodgkin. ¹

Chemical Composition and Mechanism

The active ingredient in Leukeran is chlorambucil, a nitrogen mustard derivative. It belongs to the class of alkylating agents, which work by damaging the DNA of rapidly dividing cells, such as cancer cells. By interfering with the cell’s ability to replicate, Leukeran can effectively slow or stop the growth and spread of cancerous cells. ^{Chlorambucil” target=”_blank”>2}

Medical Uses of Leukeran

Leukeran is primarily used in the treatment of the following types of cancer:

• Chronic Lymphocytic Leukemia (CLL): Leukeran is a standard treatment option for CLL, a type of leukemia that affects the lymphocytes (a type of white blood cell).
• Lymphomas: Leukeran is prescribed for the treatment of various forms of lymphomas, including Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). These are cancers that originate in the lymphatic system, which is part of the body’s immune system.
• Other Cancers: In some cases, Leukeran may be used as part of a treatment regimen for other types of cancers, such as ovarian cancer, breast cancer, and certain childhood cancers. ³

Dosage and Administration

Leukeran is available in the form of film-coated tablets, typically containing 2 mg of the active ingredient chlorambucil. The recommended dosage and administration of Leukeran depend on several factors, including the type and stage of cancer, the patient’s age, and overall health condition.

For the treatment of chronic lymphocytic leukemia (CLL), the typical starting dose is 0.1 mg per kg of body weight per day, taken orally. The dose may be adjusted based on the patient’s response and tolerance to the medication. ⁴

It is essential to follow the dosage instructions provided by your healthcare provider and not to adjust the dosage without consulting them.

Side Effects and Risks

Like other chemotherapy medications, Leukeran can cause various side effects. Some of the most common side effects of Leukeran include:

• Nausea and vomiting
• Loss of appetite
• Hair loss (alopecia)
• Fatigue
• Mouth sores
• Increased risk of infections
• Increased risk of bleeding or bruising

Serious side effects may also occur, such as bone marrow suppression, which can lead to low blood cell counts (e.g., anemia, neutropenia, thrombocytopenia). Patients should report any unusual bleeding, bruising, or signs of infection to their healthcare provider immediately. ⁵

Interactions with Other Drugs

Leukeran can interact with other medications, potentially increasing the risk of side effects or altering the effectiveness of the treatments. It is crucial to inform your healthcare provider about all the medications you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements.

Some medications that may interact with Leukeran include:

• Other chemotherapy drugs
• Certain antibiotics
• Anticoagulants (blood thinners)
• Certain antidepressants

Your healthcare provider will carefully consider potential interactions and adjust your treatment plan accordingly.

Warnings and Precautions

Leukeran should be used with caution in certa in situations and populations, such as:

• Pregnancy and Breastfeeding: Leukeran can cause birth defects and should not be used during pregnancy. Women who are pregnant or planning to become pregnant should discuss alternative treatment options with their healthcare provider. Additionally, breastfeeding should be avoided while taking Leukeran.
• Fertility Issues: Leukeran may cause infertility in both men and women, and it is recommended to discuss fertility preservation options with a healthcare provider before starting treatment.
• Pre-existing Conditions: Patients with certain medical conditions, such as kidney or liver problems, may require dose adjustments or special monitoring while taking Leukeran.

Pharmacokinetics

Leukeran is rapidly absorbed after oral administration, with peak plasma concentrations occurring within one to two hours. The medication is widely distributed throughout the body and metabolized in the liver. The half-life of chlorambucil, the active ingredient in Leukeran, is approximately 1.5 hours. ^{Chlorambucil” target=”_blank”>6}

Patient Instructions

To ensure the safe and effective use of Leukeran, patients should follow these instructions:

• Take Leukeran exactly as prescribed by your healthcare provider. Do not adjust the dosage or stop taking the medication without consulting them.
• If you miss a dose, take it as soon as you remember. However, if it’s almost time for the next dose, skip the missed dose and continue with your regular schedule. Do not double the dose to make up for a missed one.
• Avoid handling crushed or broken Leukeran tablets, as the active ingredient may be harmful if inhaled, ingested, or absorbed through the skin.
• Store Leukeran tablets at room temperature, away from moisture and heat.

Warnings and Handling Precautions

Leukeran is a potent chemotherapy medication and should be handled with care. The following precautions should be taken:

• Leukeran tablets should only be handled by healthcare professionals or patients under their direct supervision.
• Pregnant women, breastfeeding mothers, and children should avoid handling Leukeran tablets.
• Wear disposable gloves when handling Leukeran tablets to avoid skin contact.
• If tablets are crushed or broken, avoid breathing the dust and clean the area immediately.
• Discard any unused or expired Leukeran tablets according to local regulations for the disposal of hazardous waste.

Visual Identification

Leukeran is available as film-coated tablets in the following presentation:

• Round, biconvex, brown, film-coated tablets containing 2 mg of chlorambucil
• Supplied in amber glass bottles with child-resistant closures

Leukeran Tablet Visual” style=”max-width: 100%;”>

Reports and Studies

Over the years, numerous clinical studies and reports have been published on the efficacy and safety of Leukeran in treating various types of cancer. Some notable studies include:

• A randomized controlled trial evaluating the combination of Leukeran and rituximab for the treatment of chronic lymphocytic leukemia (CLL). ⁷
• A retrospective study analyzing the long-term outcomes of Leukeran in the treatment of Hodgkin lymphoma. ⁸
• A phase III clinical trial investigating the efficacy of Leukeran in combination with other chemotherapy agents for the treatment of non-Hodgkin lymphoma. ⁹

These studies and reports contribute to the understanding of Leukeran‘s safety and efficacy profiles, as well as its role in various cancer treatment regimens.

Regulatory and Approval Information

Leukeran (chlorambucil) was first approved by the U.S. Food and Drug Administration (FDA) in 1957 for the treatment of chronic lymphocytic leukemia. Over the years, it has received additional approvals for the treatment of other types of cancer, such as non-Hodgkin lymphoma and Hodgkin lymphoma.

Leukeran is currently approved in various countries around the world for the treatment of certain types of cancer. However, regulatory status and approved indications may vary depending on the country and region.

Manufacturing and Supplier Information

Leukeran is manufactured and distributed by several pharmaceutical companies worldwide. The original brand-name version of Leukeran was developed and marketed by GlaxoSmithKline (GSK). However, due to the expiration of patents, generic versions of chlorambucil are also available from various manufacturers.

It is important to note that the specific manufacturer and supplier of Leukeran may vary depending on the country or region where it is obtained.

Patient Support and Resources

For patients undergoing treatment with Leukeran, various support resources are available, including:

• Patient Assistance Programs: Some pharmaceutical companies and non-profit organizations offer patient assistance programs to help eligible patients access Leukeran or other cancer medications at a reduced cost or for free.
• Support Groups: Joining a support group can provide emotional support, practical advice, and a sense of community for patients and their families dealing with cancer.
• Educational Materials: Healthcare providers, cancer organizations, and patient advocacy groups may offer educational materials, including booklets, videos, and online resources, to help patients better understand their treatment and manage side effects.

FAQs and Common Concerns

Here are some frequently asked questions and common concerns regarding Leukeran:

• How long does Leukeran treatment typically last? The duration of Leukeran treatment can vary depending on the type and stage of cancer, as well as the patient’s response to the medication. Treatment may continue until the desired response is achieved or until significant side effects occur.
• Can Leukeran be taken with other chemotherapy drugs? Yes, Leukeran is often used in combination with other chemotherapy medications as part of a treatment regimen. However, it is crucial to inform your healthcare provider about all the medications you are taking to avoid potential interactions.
• What should I do if I experience severe side effects? If you experience severe or persistent side effects while taking Leukeran, contact your healthcare provider immediately. They may adjust your dosage or recommend alternative treatments.

Historical Background

Leukeran (chlorambucil) was first synthesized in 1953 by researchers at Lederle Laboratories, a division of American Cyanamid Company. It was one of the earliest alkylating agents developed for cancer treatment and was initially used in the treatment of chronic lymphocytic leukemia (CLL) and Hodgkin lymphoma.

In the 1960s and 1970s, Leukeran became a widely used chemotherapy drug due to its effectiveness and relatively mild side effects compared to other available treatments at the time. It played a significant role in the management of various types of lymphoma and leukemia.

Although newer and more targeted therapies have been developed in recent years, Leukeran remains an important treatment option for certain types of cancer, particularly in cases where other treatments have been ineffective or are not well-tolerated.